I would like to thank Dr David Hogan for his insightful review of this challenging topic in the December 2014 issue of The Canadian Journal of Psychiatry. 1 Quandaries about balancing potential benefits with adverse effects of cholinesterase inhibitors (CEIs) are of great interest to people who work with the elderly, especially the frailest of the elderly. It is these frail seniors who likely have the greatest risk of adverse effects, although restricted inclusion criteria (formal and informal) in originally published trials resulted in their underrepresentation. For example, Gill et al's 2 post-marketing study using administrative data in Ontario showed increased rates of syncope, bradycardia, pacemaker insertion, and hip fracture related to CEI use, which had not been predicted by the original trials. Similarly, Gill et al's study 2 found an increased risk of receiving an anticholinergic to manage incontinence related to the cholinergic properties of CEIs likely represented wider use of these agents in a frailer, less selected population.
Treatments to improve the quality of life of patients with dementia also include many interventions other than the use of CEIs. Although these are often difficult to study systematically in double-blind, placebo-controlled trials, they may be of greater overall importance. For example, I would suggest that Frank and Weir's recent article 3 on deprescribing for older adults is one of the key articles of the year, and should be read by every physician who works with the elderly. Especially toward the end of life and in the context of advanced dementia, we may do more good by increasing staff ratios, providing more comfort and warm personal care, and reducing the often unwieldy numbers of medications than by prescribing a CEI.
Lilian Thorpe, MD, PhD, FRCP
Saskatoon, Saskatchewan
REPLY

Re: Long-Term Efficacy and Toxicity of Cholinesterase Inhibitors in the Treatment of Alzheimer Disease
Dear Editor:
I would like to thank Dr Thorpe for her correspondence about my recently published paper in The Canadian Journal of Psychiatry. 1 It highlights the difficulties faced when deciding whether to recommend persisting with cholinesterase inhibitors (CEIs) therapy or stopping it in the care of older patients with multiple comorbidities. Treatment decisions do have to be individualized, and there are numerous good reasons for discontinuing these drugs. 2 It should be noted that they are frequently stopped. The accompanying paper by Maxwell et al 3 reported 1-year discontinuation rates that ranged from 40% to 65%. A study 4 from Saskatchewan found that 84% of patients treated with a CEI discontinued the drug within 40 months of starting it.
I want to use this opportunity to also mention 2 recent
Health Canada publications about very rare but serious adverse effects that may occur with CEIs. Galantamine has been reported to lead to serious skin reactions, including Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, and erythema multiforme. 5 Rhabdomyolysis and (or) neuroleptic malignant syndrome may occur with donepezil use. 6 Prescribers, patients, and families should be aware of the possibility of these adverse effects. The suspected offending agent should be discontinued as quickly as possible if there is evidence of their occurrence.
